The effect of COVID-19 infection on patients with rheumatic diseases in China

[1] Zhu N(2020)A novel coronavirus from patients with pneumonia in China, 2019 N Engl J Med 382 727-733

[2] Zhang D(2021)Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis Ann Rheum Dis 80 384-391

[3] Wang W(2021)Rheumatic disease and COVID-19: epidemiology and outcomes Nat Rev Rheumatol 17 71-72

[4] Akiyama S(2020)Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries Lancet Rheumatol 2 e250-e253

[5] Hamdeh S(2020)Hospitalization and mortality among black patients and white patients with Covid-19 N Engl J Med 382 2534-2543

[6] Micic D(2020)Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry Gastroenterology 159 481-491.e3

[7] Sakuraba A(2022)COVID-19 vaccination in patients with rheumatic diseases: vaccination rates, patient perspectives, and side effects Immun Inflamm Dis 10 269-271

[8] Hyrich KL(2020)Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Cell Res 30 2332-2343

[9] Machado PM(2019)Management strategies and future directions for systemic lupus erythematosus in adults Lancet 393 924-939

[10] Gianfrancesco MA(2021)2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Arthritis Care Res (Hoboken) 73 1168-1172

[1] Zhu N(2020)A novel coronavirus from patients with pneumonia in China, 2019 N Engl J Med 382 727-733

[2] Zhang D(2021)Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis Ann Rheum Dis 80 384-391

[3] Wang W(2021)Rheumatic disease and COVID-19: epidemiology and outcomes Nat Rev Rheumatol 17 71-72

[4] Akiyama S(2020)Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries Lancet Rheumatol 2 e250-e253

[5] Hamdeh S(2020)Hospitalization and mortality among black patients and white patients with Covid-19 N Engl J Med 382 2534-2543

[6] Micic D(2020)Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry Gastroenterology 159 481-491.e3

[7] Sakuraba A(2022)COVID-19 vaccination in patients with rheumatic diseases: vaccination rates, patient perspectives, and side effects Immun Inflamm Dis 10 269-271

[8] Hyrich KL(2020)Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Cell Res 30 2332-2343

[9] Machado PM(2019)Management strategies and future directions for systemic lupus erythematosus in adults Lancet 393 924-939

[10] Gianfrancesco MA(2021)2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Arthritis Care Res (Hoboken) 73 1168-1172